Eagle Pharmaceuticals, Inc.
EGRX
Rank in Stocks
#28502
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on... Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Share Price
$0.82
Last synced: 2026-11-10
Market Cap
$10.73M
Change (1 day)
228.00%
Change (1 year)
-36.92%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Eagle Pharmaceuticals, Inc. (EGRX)
Category
Healthcare
Operating Margin for Eagle Pharmaceuticals, Inc. (EGRX)
Operating Margin as of November 2026 TTM: 25.57%
According to Eagle Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is 25.57%. At the end of 2023 the company had an operating margin of 0.00%.
Operating Margin history for Eagle Pharmaceuticals, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 25.57% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | 25.57% | 1,488.20% |
| 2021 | 1.61% | -90.83% |
| 2020 | 17.55% | 57.54% |
| 2019 | 11.14% | -35.12% |
| 2018 | 17.17% | -45.07% |
| 2017 | 31.26% | 11.01% |
| 2016 | 28.16% | 627.65% |
| 2015 | 3.87% | -103.94% |
| 2014 | -98.21% | 58.89% |
| 2013 | -61.81% | -92.09% |
| 2012 | -781.06% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -99.24% |
DE
|
|
| 19.68% | -99.23% |
DE
|
|
| 13.26% | -99.48% |
JP
|
|
| 17.08% | -99.33% |
CH
|
|
| 14.92% | -99.42% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Eagle Pharmaceuticals, Inc.'s operating margin
What is Eagle Pharmaceuticals, Inc.'s operating margin?
Eagle Pharmaceuticals, Inc.'s operating margin is 25.57%, as of Nov 2026.
What was Eagle Pharmaceuticals, Inc.'s operating margin in 2023?
In 2023, Eagle Pharmaceuticals, Inc.'s operating margin was 0.00%, compared with 25.57% in 2022.
How has Eagle Pharmaceuticals, Inc.'s operating margin changed since 2018?
From 2018 to 2023, Eagle Pharmaceuticals, Inc.'s operating margin was highest in 2022 (25.57%) and lowest in 2023 (0.00%).
How does Eagle Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Eagle Pharmaceuticals, Inc.'s operating margin (25.57%) is higher than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.